Pednekar Lina, Valentino Alisa, Ji Yan, Tumma Nithin, Valentino Christopher, Kadoor Adarsh, Hosszu Kinga K, Ramadass Mahalakshmi, Kew Richard R, Kishore Uday, Peerschke Ellinor I B, Ghebrehiwet Berhane
Center for Infection, Immunity and Disease Mechanisms, Biosciences, Brunel University, Uxbridge, UB8 3PH London, UK; The Departments of Medicine, Stony Brook University, Stony Brook, NY 11794, United States.
The Departments of Medicine, Stony Brook University, Stony Brook, NY 11794, United States.
Mol Immunol. 2016 Jun;74:18-26. doi: 10.1016/j.molimm.2016.03.016. Epub 2016 Apr 23.
A substantial body of evidence accumulated over the past 20 years supports the concept that gC1qR is a major pathogen-associated pattern recognition receptor (PRR). This conclusion is based on the fact that, a wide range of bacterial and viral ligands are able to exploit gC1qR to either suppress the host's immune response and thus enhance their survival, or to gain access into cells to initiate disease. Of the extensive array of viral ligands that have affinity for gC1qR, the HIV-1 envelope glycoprotein gp41, and the core protein of hepatitis C virus (HCV) are of major interest as they are known to contribute to the high morbidity and mortality caused by these pathogens. While the HCV core protein binds gC1qR and suppresses T cell proliferation resulting in a significantly diminished immune response, the gp41 employs gC1qR to induce the surface expression of the NK cell ligand, NKp44L, on uninfected CD4(+) T cells, thereby rendering them susceptible to autologous destruction by NKp44 receptor expressing NK cells. Because of the potential for the design of peptide-based or antibody-based therapeutic options, the present studies were undertaken to define the gC1qR interaction sites for these pathogen-associated molecular ligands. Employing a solid phase microplate-binding assay, we examined the binding of each viral ligand to wild type gC1qR and 11 gC1qR deletion mutants. The results obtained from these studies have identified two major HCV core protein sites on a domain of gC1qR comprising of residues 144-148 and 196-202. Domain 196-202 in turn, is located in the last half of the larger gC1qR segment encoded by exons IV-VI (residues 159-282), which was proposed previously to contain the site for HCV core protein. The major gC1qR site for gp41 on the other hand, was found to be in a highly conserved region encoded by exon IV and comprises of residues 174-180. Interestingly, gC1qR residues 174-180 also constitute the cell surface-binding site for soluble gC1qR (sgC1qR), which can bind to the cell surface in an autocrine/paracrine manner via surface expressed fibrinogen or other membrane molecules. The identification of the sites for these viral ligands should therefore provide additional targets for the design of peptide-based or antigen-based therapeutic strategies.
在过去20年里积累的大量证据支持了这样一种观念,即gC1qR是一种主要的病原体相关模式识别受体(PRR)。这一结论基于以下事实:多种细菌和病毒配体能够利用gC1qR来抑制宿主的免疫反应从而提高它们的存活率,或者进入细胞引发疾病。在对gC1qR具有亲和力的大量病毒配体中,HIV-1包膜糖蛋白gp41和丙型肝炎病毒(HCV)的核心蛋白备受关注,因为它们已知会导致这些病原体引发的高发病率和高死亡率。虽然HCV核心蛋白结合gC1qR并抑制T细胞增殖,导致免疫反应显著减弱,但gp41利用gC1qR诱导未感染的CD4(+) T细胞表面表达NK细胞配体NKp44L,从而使它们易被表达NKp44受体的NK细胞进行自体破坏。由于基于肽或基于抗体的治疗方案具有设计潜力,因此开展了本研究以确定这些病原体相关分子配体的gC1qR相互作用位点。采用固相微孔板结合试验,我们检测了每种病毒配体与野生型gC1qR和11种gC1qR缺失突变体的结合情况。从这些研究中获得的结果确定了gC1qR一个结构域上的两个主要HCV核心蛋白位点,该结构域由144 - 148位和196 - 202位残基组成。196 - 202结构域又位于由外显子IV - VI编码的较大gC1qR片段的后半部分(159 - 282位残基),先前有人提出该区域包含HCV核心蛋白的位点。另一方面,发现gp41在gC1qR上的主要位点位于由外显子IV编码的一个高度保守区域,由174 - 180位残基组成。有趣的是,gC1qR的174 - 180位残基也构成了可溶性gC1qR(sgC1qR)的细胞表面结合位点,sgC1qR可以通过表面表达的纤维蛋白原或其他膜分子以自分泌/旁分泌方式结合到细胞表面。因此,这些病毒配体位点的确定应为基于肽或基于抗原的治疗策略设计提供额外的靶点。